Article Information
History
- November 30, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Christopher E. Lietz1,
- Erik T. Newman1,
- Andrew D. Kelly2,
- Santiago A. Lozano-Calderon1,
- David H. Ebb3,
- Kevin A. Raskin1,
- Gregory M. Cote4,
- Edwin Choy4,
- G. Petur Nielsen5,
- Benjamin Haibe-Kains6,
- Martin J. Aryee5 and
- Dimitrios Spentzos1,*
- 1Department of Orthopaedic Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
- 2Foundation Medicine, Cambridge, MA
- 3Division of Pediatric Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
- 4Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
- 5Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
- 6Department of Medical Biophysics, Princess Margaret Cancer Centre, University of Toronto, M5G 2M9 ON, Canada
- ↵*To whom correspondence should be addressed: Dimitrios Spentzos (dspentzos{at}mgh.harvard.edu).
Posted November 30, 2020.
Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in osteosarcoma
